Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Position Boosted by TD Asset Management Inc

Key Points

• TD Asset Management Inc increased its stake in Agios Pharmaceuticals by 7.5%, acquiring an additional 12,400 shares, bringing its total ownership to 178,072 shares valued at approximately $5.2 million.
• Several large investors, including Vanguard Group and Deutsche Bank AG, have also adjusted their positions in Agios Pharmaceuticals, demonstrating renewed interest in the company.
• Agios Pharmaceuticals reported a quarterly loss of $1.93 EPS, falling short of the expected ($1.74 EPS), despite surpassing revenue expectations with $12.5 million in revenue.

TD Asset Management Inc grew its stake in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 7.5% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 178,072 shares of the biopharmaceutical company's stock after buying an additional 12,400 shares during the period. TD Asset Management Inc owned 0.31% of Agios Pharmaceuticals worth $5,218,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. GF Fund Management CO. LTD. bought a new position in shares of Agios Pharmaceuticals in the fourth quarter worth approximately $39,000. CWM LLC lifted its position in Agios Pharmaceuticals by 150.2% during the first quarter. CWM LLC now owns 1,659 shares of the biopharmaceutical company's stock valued at $49,000 after buying an additional 996 shares during the period. Sterling Capital Management LLC raised its position in shares of Agios Pharmaceuticals by 818.0% in the 4th quarter. Sterling Capital Management LLC now owns 1,781 shares of the biopharmaceutical company's stock worth $59,000 after purchasing an additional 1,587 shares during the last quarter. Summit Investment Advisors Inc. raised its position in shares of Agios Pharmaceuticals by 7.1% in the 4th quarter. Summit Investment Advisors Inc. now owns 5,913 shares of the biopharmaceutical company's stock worth $194,000 after purchasing an additional 394 shares during the last quarter. Finally, GAMMA Investing LLC raised its position in Agios Pharmaceuticals by 9,296.6% in the 1st quarter. GAMMA Investing LLC now owns 8,175 shares of the biopharmaceutical company's stock worth $240,000 after buying an additional 8,088 shares during the last quarter.

Insider Transactions at Agios Pharmaceuticals

In other Agios Pharmaceuticals news, CEO Brian Goff sold 18,700 shares of the business's stock in a transaction dated Tuesday, June 24th. The stock was sold at an average price of $33.54, for a total transaction of $627,198.00. Following the transaction, the chief executive officer owned 105,401 shares in the company, valued at $3,535,149.54. The trade was a 15.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Tsveta Milanova sold 2,770 shares of the business's stock in a transaction dated Tuesday, June 24th. The stock was sold at an average price of $33.54, for a total value of $92,905.80. Following the transaction, the insider owned 26,122 shares in the company, valued at approximately $876,131.88. This represents a 9.59% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 46,363 shares of company stock valued at $1,619,654 in the last ninety days. Company insiders own 4.30% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on AGIO shares. Scotiabank decreased their target price on Agios Pharmaceuticals from $71.00 to $65.00 and set a "sector outperform" rating for the company in a research report on Monday, July 28th. Wall Street Zen downgraded Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Monday, May 19th. Finally, Bank of America reduced their target price on Agios Pharmaceuticals from $52.00 to $51.00 and set a "buy" rating on the stock in a research note on Tuesday, July 22nd. One analyst has rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the company. According to MarketBeat, Agios Pharmaceuticals has an average rating of "Moderate Buy" and a consensus target price of $56.33.

Agios Pharmaceuticals Stock Up 0.1%

NASDAQ AGIO traded up $0.05 during trading hours on Tuesday, hitting $36.21. 1,173,560 shares of the company were exchanged, compared to its average volume of 720,392. The firm has a market cap of $2.10 billion, a price-to-earnings ratio of 3.29 and a beta of 0.80. Agios Pharmaceuticals, Inc. has a 52-week low of $23.42 and a 52-week high of $62.58. The company has a 50 day moving average of $35.81 and a two-hundred day moving average of $32.60.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last released its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported ($1.93) earnings per share for the quarter, missing the consensus estimate of ($1.74) by ($0.19). The firm had revenue of $12.50 million during the quarter, compared to analysts' expectations of $9.46 million. Agios Pharmaceuticals had a net margin of 1,590.42% and a negative return on equity of 3.49%. On average, equities research analysts predict that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current year.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.